LEADING ARTICLE

Can immunotherapy by gene transfer tip the balance against colorectal cancer?

S M TODRYK, H CHONG, R G VILE

Laboratory of Molecular Therapy,Imperial Cancer Research Fund Molecular Oncology Unit,Imperial College School of Medicine,Hammersmith Hospital, London W12 0NN, UK

H PANDHA, N R LEMOINE

Laboratory of Molecular Pathology,Imperial Cancer Research Fund Molecular Oncology Unit,Imperial College School of Medicine,Hammersmith Hospital, London W12 0NN, UK

Correspondence to: Dr Stephen Todryk (email: s.todryk{at}icrf.icnet.uk).

Gene therapy, in particular the transfer of genes encoding immunostimulatory molecules (cytokines and costimulatory molecules) as well as selectively cytotoxic enzymes and DNA vaccination, has the potential of enhancing cell mediated immune responses against tumours including those of colorectal origin. Genes can be transferred using viral vectors either to cultured tumour cells in vitro that can be returned to the patient as a "cancer vaccine", or directly to tumour cells in vivo. Vaccination with DNA constructs expressing specific tumour antigens characteristic of colorectal neoplasia can trigger immune recognition and destruction of tumour cells. The aim is to tip the balance from protumour to antitumour mechanisms by generating a local immune response and systemic antitumour immune memory to destroy metastases. Studies in murine models, combined with human studies, show that such approaches could become an adjunct to current treatments for human colorectal cancer in the near future.
(GUT 1998;43:445-449)